Sonnet Biotherapeutics Revenue vs. Shares Owned By Insiders

SONN Stock  USD 1.42  0.02  1.39%   
Based on Sonnet Biotherapeutics' profitability indicators, Sonnet Biotherapeutics Holdings may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Sonnet Biotherapeutics' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2011-03-31
Previous Quarter
0.0
Current Value
9.1 M
Quarterly Volatility
M
 
Credit Downgrade
 
Yuan Drop
 
Covid
As of the 25th of December 2024, Price To Sales Ratio is likely to drop to 1.18. In addition to that, Days Sales Outstanding is likely to drop to 3.67. At this time, Sonnet Biotherapeutics' Interest Income is very stable compared to the past year. As of the 25th of December 2024, Change To Netincome is likely to grow to about 10.4 M, while Accumulated Other Comprehensive Income is likely to drop (212.2 K).
For Sonnet Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sonnet Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sonnet Biotherapeutics Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sonnet Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sonnet Biotherapeutics Holdings over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.35)
Revenue Per Share
0.019
Quarterly Revenue Growth
(0.50)
Return On Assets
(0.97)
Return On Equity
(2.65)
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sonnet Biotherapeutics Shares Owned By Insiders vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sonnet Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Sonnet Biotherapeutics value to that of its competitors to determine the firm's financial worth.
Sonnet Biotherapeutics Holdings is rated third in revenue category among its peers. It is rated below average in shares owned by insiders category among its peers . The ratio of Revenue to Shares Owned By Insiders for Sonnet Biotherapeutics Holdings is about  14,328 . At this time, Sonnet Biotherapeutics' Total Revenue is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sonnet Biotherapeutics' earnings, one of the primary drivers of an investment's value.

Sonnet Revenue vs. Competition

Sonnet Biotherapeutics Holdings is rated third in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 687.29 Million. Sonnet Biotherapeutics adds roughly 18,626 in revenue claiming only tiny portion of equities under Health Care industry.
YS BiopharmSONN0.0%YS Biopharm100.0%Navidea0.0%100%

Sonnet Shares Owned By Insiders vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Sonnet Biotherapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
18.63 K
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Sonnet Biotherapeutics

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
1.30 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Sonnet Shares Owned By Insiders Comparison

1.3081.4240.0935.43100%
Sonnet Biotherapeutics is currently under evaluation in shares owned by insiders category among its peers.

Sonnet Biotherapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sonnet Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sonnet Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Sonnet Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Sonnet Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-202.1 K-212.2 K
Operating Income-11.8 M-4.7 M
Income Before Tax-7.4 M-4.9 M
Total Other Income Expense Net4.4 M-162.9 K
Net Loss-7.4 M-4.9 M
Net Loss-17.4 M-18.3 M
Non Operating Income Net Other-556.1 K-528.3 K
Net Loss-16.1 M-16.9 M
Income Tax Expense162.9 K154.7 K
Interest Income606.2 K955 K
Net Interest Income-187.3 K-177.9 K
Change To Netincome9.9 M10.4 M
Net Loss(11.35)(15,593)
Income Quality 1.16  0.16 
Net Income Per E B T 0.76  0.87 

Sonnet Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sonnet Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sonnet Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sonnet Biotherapeutics' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Sonnet Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Financial Widgets Now

   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Use Investing Themes to Complement your Sonnet Biotherapeutics position

In addition to having Sonnet Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run CAD Crypto Assets Thematic Idea Now

CAD Crypto Assets
CAD Crypto Assets Theme
An experimental p2p digital currency that is accepted by many vendors in Canadian Dollar. The CAD Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize CAD Crypto Assets Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock:
Check out World Market Map.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
To fully project Sonnet Biotherapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sonnet Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sonnet Biotherapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Sonnet Biotherapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Sonnet Biotherapeutics investors may work on each financial statement separately, they are all related. The changes in Sonnet Biotherapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sonnet Biotherapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.